Filter

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Carolyn Fennell x
Clear All Modify Search
Nandini Shankara Narayana Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Nandini Shankara Narayana in
Google Scholar
PubMed Close
,
Lam P Ly Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Lam P Ly in
Google Scholar
PubMed Close
,
Veena Jayadev Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Veena Jayadev in
Google Scholar
PubMed Close
,
Carolyn Fennell Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Carolyn Fennell in
Google Scholar
PubMed Close
,
Sasha Savkovic Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Sasha Savkovic in
Google Scholar
PubMed Close
,
Ann J Conway Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by Ann J Conway in
Google Scholar
PubMed Close
, and
David J Handelsman Andrology Department, Concord Hospital and, ANZAC Research Institute, University of Sydney, Sydney, Australia

Search for other papers by David J Handelsman in
Google Scholar
PubMed Close

Objective

To define the optimized inter-injection interval of injectable testosterone undecanoate (TU) treatment for hypogonadal and transmen based on individual dose titration in routine clinical practice.

Design and methods

A prolective observational study of consecutive TU injections in men undergoing testosterone replacement therapy for pathological hypogonadism or masculinization of female-to-male transgender (transmen) subject to individual dosing titration to achieve a stable replacement regimen.

Results

From 2006 to 2019, 6899 injections were given to 325 consecutive patients. After excluding the 6-week loading dose, 6300 injections were given to 297 patients who had at least three and a median of 14 injections. The optimal injection interval (mean of last three injection intervals) had a median of 12.0 weeks (interquartile range 10.4–12.7 weeks). The interval was significantly influenced by age and body size (body surface area, BSA) but not by diagnosis or trough serum LH, FSH, and SHBG. Longer (≥14 weeks; 68/297, 23%), but not shorter (≤10 weeks; 22/297, 7.4%), intervals were weakly correlated with age but not diagnosis or other covariables. Low blood hemoglobin increased with trough serum testosterone to reach plateau once testosterone was about 10 nmol/L or higher.

Conclusion

Optimal intervals between TU injection after individual titration resulted in the approved 12-week interval in 70% of patients with only minor influence for clinical application of BSA and not of trough serum LH, FSH, and SHBG. Individually optimized inter-injection interval did not differ between men with primary or secondary hypogonadism or transmen.

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-21-0109
Volume/Issue:
Volume 10: Issue 7
Open access